Literature DB >> 83964

Requirements for beta1H globulin and C3b inactivator in the control of the alternative complement pathway in human serum.

K Whaley, R A Thompson.   

Abstract

Using beta1H-depleted and C3b inactivator (C3b1NA)-deficient sera we have investigated the regulatory roles of beta1H and C3bINA in the turnover of the alternative pathway. Spontaneous turnover of C3 and factor B occurred in both beta1H-depleted and C3bINA-deficient sera. In neither case was C3d generated. Prevention of activation could be achieved by the addition of the missing protein, but not by increasing the concentration of the remaining protein. Thus both beta1H and C3bINA must be present simultaneously to prevent spontaneous activation of the alternative pathway.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 83964      PMCID: PMC1457447     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  26 in total

1.  Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis.

Authors:  L H Perrin; P H Lambert; P A Miescher
Journal:  J Clin Invest       Date:  1975-07       Impact factor: 14.808

2.  The immune-adherence phenomenon; an immunologically specific reaction between microorganisms and erythrocytes leading to enhanced phagocytosis.

Authors:  R A NELSON
Journal:  Science       Date:  1953-12-18       Impact factor: 47.728

3.  A stoichiometric assay for the fourth component of complement in whole human serum using EAC'la-gp and functionally pure human second component.

Authors:  S Ruddy; K F Austen
Journal:  J Immunol       Date:  1967-12       Impact factor: 5.422

4.  Effect of ageing of serum on consumption of antibody by beta-1C-globulin determinants; evidence for circulating breakdown products in glomerulonephritis.

Authors:  C D West; S Winter; J Forristal; N C Davis
Journal:  Clin Exp Immunol       Date:  1968-01       Impact factor: 4.330

5.  Control of the amplification convertase of complement by the plasma protein beta1H.

Authors:  J M Weiler; M R Daha; K F Austen; D T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  1976-09       Impact factor: 11.205

6.  Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms.

Authors:  D T Fearon; K F Austen
Journal:  Proc Natl Acad Sci U S A       Date:  1977-04       Impact factor: 11.205

7.  Properdin: initiation of alternative complement pathway.

Authors:  D T Fearon; K F Austen
Journal:  Proc Natl Acad Sci U S A       Date:  1975-08       Impact factor: 11.205

8.  Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution.

Authors:  M K Pangburn; R D Schreiber; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1977-07-01       Impact factor: 14.307

9.  ISOLATION OF BETA IF-GLOBULIN FROM HUMAN SERUM AND ITS CHARACTERIZATION AS THE FIFTH COMPONENT OF COMPLEMENT.

Authors:  U R NILSSON; H J MUELLER-EBERHARD
Journal:  J Exp Med       Date:  1965-08-01       Impact factor: 14.307

10.  C3 proactivator convertase and its mode of action.

Authors:  H J Müller-Eberhard; O Götze
Journal:  J Exp Med       Date:  1972-04-01       Impact factor: 14.307

View more
  11 in total

1.  Combined homozygous factor H and heterozygous C2 deficiency in an Italian family.

Authors:  M Brai; G Misiano; S Maringhini; I Cutaja; G Hauptmann
Journal:  J Clin Immunol       Date:  1988-01       Impact factor: 8.317

2.  CNBr cleavage of the light chain of human complement factor I and alignment of the fragments.

Authors:  J M Yuan; L M Hsiung; J Gagnon
Journal:  Biochem J       Date:  1986-01-15       Impact factor: 3.857

Review 3.  The quest for an intrinsic C3 activating factor in human glomerular disease.

Authors:  J L Roberts; E J Lewis
Journal:  Surv Immunol Res       Date:  1982

4.  Hypocomplementaemia due to a genetic deficiency of beta 1H globulin.

Authors:  R A Thompson; M H Winterborn
Journal:  Clin Exp Immunol       Date:  1981-10       Impact factor: 4.330

5.  C3b inactivator deficiency with immune complex manifestations.

Authors:  P Solal-Celigny; M Laviolette; J Hebert; P C Atkins; M Sirois; G Brun; G Lehner-Netsch; J M Delâge
Journal:  Clin Exp Immunol       Date:  1982-01       Impact factor: 4.330

6.  Relative importance of C3b inactivator and beta 1H globulin in the modulation of the properdin amplification loop in systemic lupus erythematosus.

Authors:  K Whaley; P H Schur; S Ruddy
Journal:  Clin Exp Immunol       Date:  1979-06       Impact factor: 4.330

7.  Genetic and environmental factors influencing the human factor H plasma levels.

Authors:  Jorge Esparza-Gordillo; José Manuel Soria; Alfonso Buil; Laura Almasy; John Blangero; Jordi Fontcuberta; Santiago Rodríguez de Córdoba
Journal:  Immunogenetics       Date:  2004-04-30       Impact factor: 2.846

8.  Evaluation of alternative pathway and factor B haemolytic activities in patients with systemic lupus erythematosus: correlations with the alternative pathway regulatory proteins.

Authors:  M T Aguado; L H Perrin; R Ramirez; P A Miescher; P H Lambert
Journal:  Clin Exp Immunol       Date:  1980-12       Impact factor: 4.330

9.  Complement activation in chronic liver disease.

Authors:  L E Munoz; D De Villiers; D Markham; K Whaley; H C Thomas
Journal:  Clin Exp Immunol       Date:  1982-03       Impact factor: 4.330

Review 10.  Inherited Kidney Complement Diseases.

Authors:  Mathieu Lemaire; Damien Noone; Anne-Laure Lapeyraque; Christoph Licht; Véronique Frémeaux-Bacchi
Journal:  Clin J Am Soc Nephrol       Date:  2021-02-03       Impact factor: 10.614

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.